Differential seminal plasma proteome signatures of acute lymphoblastic leukemia survivors

Reprod Biol. 2019 Dec;19(4):322-328. doi: 10.1016/j.repbio.2019.11.002. Epub 2019 Nov 8.

Abstract

With advances in therapeutic methods, there is a high survival rate among leukemia patients, of an extent more than 80%. However, chemotherapeutic drugs used to treat these patients have adverse effects on their overall health profile including fertility. The primary aim of this study was to identify differentially expressed proteins in seminal plasma of acute lymphoblastic leukemia (ALL) survivors compared to age-matched healthy controls, which can provide molecular basis of idiopathic infertility in such survivors. Differential proteome profiling was performed by 2D-differential in-gel electrophoresis, protein spots were identified by mass spectrometry and selective differentially expressed proteins (DEPs) were validated by western blotting and ELISA method. Out of eight DEPs identified, five proteins (isocitrate dehydrogenase 1, semenogelin 1, lactoferrin, prolactin-inducible protein, and human serum albumin) were upregulated and three (pepsinogen, prostate specific antigen and prostatic acid phosphatase) were downregulated. Expression profiles of these proteins are suggestive of reduction in semen quality in ALL survivors and can further be explored to determine their fertility status.

Keywords: Differential proteomics; ELISA; Lactoferrin; Leukemia survivors; Normozoospermia; Prolactin inducible protein; Semenogelin 1.

MeSH terms

  • Cancer Survivors*
  • Case-Control Studies
  • Humans
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma*
  • Proteome*
  • Semen / metabolism*
  • Young Adult

Substances

  • Proteome